The subject of the present invention is a weakly corrosive and weakly coloured sulfonic acid, with an APHA colour index of less than 20, comprising chlorides and nitrites in a chloride/sulfonic acid molar ratio of between 1 ppm and 200 ppm, and a nitrite/sulfonic acid molar ratio of between 200 ppm and 6000 ppm, limits inclusive.

The subject of the present invention is a weakly corrosive and weakly coloured sulfonic acid, with an APHA colour index of less than 20, comprising chlorides and nitrites in a chloride/sulfonic acid molar ratio of between 1 ppm and 200 ppm, and a nitrite/sulfonic acid molar ratio of between 200 ppm and 6000 ppm, limits inclusive.

Acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, and acid addition salt of apomorphine isobutyrate salts are disclosed. Also disclosed are pharmaceutical compositions (e.g., unit dosage forms, e.g., films) containing acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate. Further disclosed are methods of use of acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate.

The invention relates to a stabilizer for L-012 or a salt thereof, a stabilization method for L-012 or a salt thereof, coexisting with the stabilizer and L-012 or a salt thereof, and the like. The stabilizer is represented by Formula [1]: ##STR00001##
wherein p pieces of M1 each independently represent a hydrogen atom or an alkali metal atom, q pieces of R1 each independently represent a hydroxy group or a sulfonic acid group, m represents 0 or 1, p represents an integer of 1 to 3, q represents an integer of 0 to 4, Y represents a nitrogen atom or a CH group (a methine group), and Z represents an aryl group having a specific structure or a pyrazolyl group having a specific structure.

The invention relates to a stabilizer for L-012 or a salt thereof, a stabilization method for L-012 or a salt thereof, coexisting with the stabilizer and L-012 or a salt thereof, and the like. The stabilizer is represented by Formula [1]: ##STR00001##
wherein p pieces of M1 each independently represent a hydrogen atom or an alkali metal atom, q pieces of R1 each independently represent a hydroxy group or a sulfonic acid group, m represents 0 or 1, p represents an integer of 1 to 3, q represents an integer of 0 to 4, Y represents a nitrogen atom or a CH group (a methine group), and Z represents an aryl group having a specific structure or a pyrazolyl group having a specific structure.

Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS

##STR00001##

is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4-fluoro butyrophenone (XI, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS

##STR00001##

is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4-fluoro butyrophenone (XI, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.

The present invention provides a preservative composition to prevent and/or reduce corrosion on a metal surface comprising an anhydride-derived amide and an oil and/or a solvent, wherein the anhydride-derived amide is present in an amount in the range of from 0.01-50 wt %, based on the total weight of the preservative composition. The invention also provides a preservative composition comprising in addition a sulfonate composition; a metal article having a coating thereon which coating comprises the present preservative composition; and the use of the present preservative composition to prevent and/or reduce corrosion on a metal surface.

The present invention provides a preservative composition to prevent and/or reduce corrosion on a metal surface comprising an anhydride-derived amide and an oil and/or a solvent, wherein the anhydride-derived amide is present in an amount in the range of from 0.01-50 wt %, based on the total weight of the preservative composition. The invention also provides a preservative composition comprising in addition a sulfonate composition; a metal article having a coating thereon which coating comprises the present preservative composition; and the use of the present preservative composition to prevent and/or reduce corrosion on a metal surface.